DuPont de Nemours, Inc. · NYSE:DD

DuPont de Nemours — DuPont — Q2 2013 Earnings Presentation

30 slides from DuPont de Nemours's earnings presentation, Jul 23, 2013

  1. Slide 1: DuPont 2Q 2013 Earnings Conference Call

    DuPont 2Q 2013 Earnings Conference Call July 23, 2013 1

  2. Slide 2: Regulation G, Forward Looking Statements, Developing Markets

    Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and

  3. Slide 3: 2Q 2013 Financial Highlights

    2Q 2013 Financial Highlights $ in billions, except EPS 2Q13 vs. 2Q12 YTD13 vs. ‘12 EPS Operating earnings* $1.28 (15)% $2.84 (10)% GAAP earnings $1.10 $2.58 Segment Operating Earnings* $1.9 (17)% $4.1 (12)% Consolidated Net Sales $9.8 (1)% $20.3 1% Volume 1% 2% Local Prices (1)% 0% Currency Impact (

  4. Slide 4: Global Sales – Regional Highlights

    Global Sales – Regional Highlights 2Q 2013 Sales by Region 2Q 2013 Sales YOY % CHG Region % Latin America 9% Worldwide (1) Developed Asia U.S. & Canada 8% U.S. & Canada 1 49% Non-U.S. & Canada (2) Developing Asia Developing Markets 1 13% Developing Asia (5)* Developed Developing Developing EMEA 6 EM

  5. Slide 5: 2Q 2013 Segment Operating Earnings Variance

    2Q 2013 Segment Operating Earnings* Variance $14 $1 ($330) ($44) ($9) ($8) ($6) ($4) $2,225** $1,839** 2Q12 Other IB Perf Chem N&H S&P Perf Mtls Ag E&C 2Q13 Key  Lower Perf Chem earnings largely due to Ti02 price declines  N&H and Ag results impacted by cool, wet spring and higher input costs Take

  6. Slide 6: 2Q 2013 Operating EPS Variance

    2Q 2013 Operating EPS* Variance ($0.31) $0.02 $0.02 $0.03 $0.02 $1.50 $1.28 2Q12 EPS Segment results EGL Corp exp Lower shares Other 2Q13 EPS  Lower Perf Chem results were primary driver for EPS decline Key  Segment results include a ($.03) currency impact Takeaways  Restructuring savings deliver

  7. Slide 7: Balance Sheet and Cash

    Balance Sheet and Cash June 30, 2013 Free Cash Flow Free Cash Flow* YTD12 YTD13 • Increase in seasonal FCF outflow due to 0.0 lower cash earnings and higher Ag working -1.0 $ Billions capital, partially offset by lower pension -2.0 contributions • Capex spend: $0.8B YTD13; ~$1.9B FY -3.0 -4.0 Strong

  8. Slide 8: Next Steps in the Transformation of DuPont

    Next Steps in the Transformation of DuPont To A Higher Growth, Higher Value Company • Realignment of Senior Leaders • Exploring Strategic Alternatives for Performance Chemicals Redesigned Performance Danisco Cost Structure Coatings Acquisition $2 billion lower Divestiture Aligned With Strategic Plan

  9. Slide 9: Integrated Science - the Growth Engine of DuPont

    Integrated Science - the Growth Engine of DuPont Particle & Inorganic / Gene Metabolic Recombination Dispersion Organic Engineering Science Fluoro Synthesis & Regulation Chemical & Biochemistry Agronomy Genomics Polymer Synthesis Rheology Nutrition Cell / Tissue Catalysis Control Science Culture Pol

  10. Slide 10: Three Strategic Priorities

    Strategic Plan to Increase the Value of DuPont Generate Superior Shareholder Returns by Building and Leveraging World-Leading Positions Across Three Attractive Spaces Bio-based Advanced Ag & Nutrition Industrials Materials Extend our leadership across the Develop world-leading high-value, science-dr

  11. Slide 11: APPENDIX – Segment Results

    APPENDIX – Segment Results The segment slides that follow and related commentary on second quarter 2013 segment results can be found on the Earnings News Release link on the Investor Center website at www.dupont.com 11

  12. Slide 12: Agriculture

    Agriculture Pioneer, Crop Protection 2Q Sales * 2Q and 1H Comments 5.0  2Q Sales +7%, operating earnings 1% lower 4.0  Higher seed input costs pressured margins $ in Billions 3.0  Accelerated pace of corn seed sales in 1Q  1H sales +11%, operating earnings +8% 2.0  1H seed sales up 11% on prici

  13. Slide 13: Electronics & Communications

    Electronics & Communications 2Q Sales * 2Q Comments 1.0  Sales down 18%, primarily on lower sales into PV 0.8  Lower silver prices contributed to reduced top $ in Billions 0.6 line sales 0.4  Operating earnings down $4 million on lower sales 0.2  2Q13 operating earnings included $20 million 0.0

  14. Slide 14: Industrial Biosciences

    Industrial Biosciences 2Q Sales * 2Q Comments 0.4  Sales 1% higher on higher price 0.3  Strong demand and higher prices for Sorona® in $ in Billions carpeting were offset by lower enzyme volumes 0.2 for ethanol and animal nutrition 0.1  Operating earnings were up 2% as sales growth was partially

  15. Slide 15: Nutrition & Health

    Nutrition & Health 2Q Sales * 2Q Comments 1.0  Sales 2% lower with higher prices offset by unfavorable 0.8 currency, lower enablers volume and the impact of $ in Billions manufacturing site closures 0.6  Lower enablers volume due to market softness in Europe and 0.4 Asia and unseasonably cool weat

  16. Slide 16: Performance Chemicals

    Performance Chemicals Titanium Technologies (DTT), Chemicals & Fluoroproducts (DC&F) 2Q Sales * 2Q Comments  Sales down 9% primarily from lower Ti02 prices 2.0  Ti02 volumes up 12% YoY, 18% sequentially $ in Billions 1.5  Volume gains in fluoropolymers more than offset by 1.0 lower demand and pri

  17. Slide 17: Performance Materials

    Performance Materials Performance Polymers (DPP), Packaging & Industrial Polymers (P&IP) 2Q Sales * 2Q Comments 2.0  Sales down 2% with slightly lower prices partially offset by higher packaging volumes $ in Billions  Automotive demand mixed with Europe, Japan and 1.6 Korea weakness offset by stre

  18. Slide 18: Safety & Protection

    Safety & Protection Protection Technologies (DPT), Building Innovations (BI), Sustainable Solutions (DSS) 2Q Sales * 2Q Comments 1.2 1.0  Sales up 3% on higher volumes, partially offset by unfavorable currency and prices $ in Billions 0.8 0.6  Higher volume primarily reflects increased demand for

  19. Slide 19: The miracles of science

    The miracles of science” 19

  20. Slide 20: DuPont Second Quarter 2013 Earnings Segment Commentary

    DuPont Second Quarter 2013 Earnings Segment Commentary This data should be read in conjunction with the Company’s second quarter earnings news release dated July 23, 2013 and DuPont 2Q2013 Earnings Conference Call presentation materials posted on the Investor Center website at www.dupont.com. 1

  21. Slide 21: Agriculture

    Agriculture Pioneer, Crop Protection 2Q Sales * 2Q and 1H Comments 5.0  2Q Sales +7%, operating earnings 1% lower 4.0  Higher seed input costs pressured margins $ in Billions 3.0  Accelerated pace of corn seed sales in 1Q  1H sales +11%, operating earnings +8% 2.0  1H seed sales up 11% on prici

  22. Slide 22: Pioneer Field360 Select launch commentary

    In the 2nd quarter, we launched our next generation services offering, Pioneer®Field360™ Select software, to which we continue to add functionality that growers value. As a leader in precision farming services, we provide crop analytics on more than 10 million customer acres annually, and this sprin

  23. Slide 23: Corn share gains and crop protection commentary

    corn share gain in each of the past summer and safrinha seasons, and we are seeing rapid adoption of hybrids with Optimum® Intrasect® insect control protection. Also, our insect control portfolio, led by Rynaxypyr®, continues to perform well, and we are planning wider-scale testing of our Lumigen® s

  24. Slide 24: Electronics & Communications

    Electronics & Communications 2Q Sales * 2Q Comments 1.0  Sales down 18%, primarily on lower sales into PV 0.8  Lower silver prices contributed to reduced top $ in Billions 0.6 line sales 0.4  Operating earnings down $4 million on lower sales 0.2  2Q13 operating earnings included $20 million 0.0

  25. Slide 25: Industrial Biosciences

    Industrial Biosciences 2Q Sales * 2Q Comments 0.4  Sales 1% higher on higher price 0.3  Strong demand and higher prices for Sorona® in $ in Billions carpeting were offset by lower enzyme volumes 0.2 for ethanol and animal nutrition 0.1  Operating earnings were up 2% as sales growth was partially

  26. Slide 26: Nutrition & Health

    Nutrition & Health 2Q Sales * 2Q Comments 1.0  Sales 2% lower with higher prices offset by unfavorable 0.8 currency, lower enablers volume and the impact of manufacturing site closures $ in Billions 0.6  Lower enablers volume due to market softness in Europe and 0.4 Asia and unseasonably cool weat

  27. Slide 27: Performance Chemicals

    Performance Chemicals Titanium Technologies (DTT), Chemicals & Fluoroproducts (DC&F) 2Q Sales * 2Q Comments  Sales down 9% primarily from lower Ti02 prices 2.0  Ti02 volumes up 12% YoY, 18% sequentially $ in Billions 1.5  Volume gains in fluoropolymers more than offset by 1.0 lower demand and pri

  28. Slide 28: Performance Materials

    Performance Materials Performance Polymers (DPP), Packaging & Industrial Polymers (P&IP) 2Q Sales * 2Q Comments 2.0  Sales down 2% with slightly lower prices partially offset by higher packaging volumes $ in Billions  Automotive demand mixed with Europe, Japan and 1.6 Korea weakness offset by stre

  29. Slide 29: Safety & Protection

    Safety & Protection Protection Technologies (DPT), Building Innovations (BI), Sustainable Solutions (DSS) 2Q Sales * 2Q Comments 1.2 1.0  Sales up 3% on higher volumes, partially offset by unfavorable currency and prices $ in Billions 0.8 0.6  Higher volume primarily reflects increased demand for

  30. Slide 30: Non-GAAP and Forward-Looking Statements notes

    other companies. Reconciliations of non-GAAP measures to GAAP are provided in schedules A, C and D to the Company’s second quarter 2013 Earnings News Release, available on the Investor Center website at http://www.dupont.com. Forward-Looking Statements: This news release contains forward-looking sta

DuPont — Q2 2013 Earnings Presentation on 6ix